Cargando…

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy

BACKGROUND: Before the advent of neoadjuvant chemotherapy, radiotherapy and surgery alone were associated with a high risk of uncontrolled locoregional relapses in locally advanced breast cancer (LABC). MATERIAL AND METHODS: In the 1990s we initiated two neoadjuvant protocols, where patients with LA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eikesdal, Hans P., Knappskog, Stian, Aas, Turid, Lønning, Per E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245178/ https://www.ncbi.nlm.nih.gov/pubmed/24909504 http://dx.doi.org/10.3109/0284186X.2014.922215

Ejemplares similares

Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
por: Chrisanthar, Ranjan, et al.
Publicado: (2011)

High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function
por: Yndestad, Synnøve, et al.
Publicado: (2017)

Constitutional Mosaic Epimutations - a hidden cause of cancer?
por: Lønning, Per E., et al.
Publicado: (2019)

Chemosensitivity and p53; new tricks by an old dog
por: Lønning, Per E, et al.
Publicado: (2012)

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
por: Løes, Inger Marie, et al.
Publicado: (2016)

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines
por: Yndestad, Synnøve, et al.
Publicado: (2017)

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
por: Knappskog, Stian, et al.
Publicado: (2012)

Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines
por: Huun, Johanna, et al.
Publicado: (2017)

DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival
por: Pedersen, Christine Aaserød, et al.
Publicado: (2022)

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
por: Venizelos, Andreas, et al.
Publicado: (2022)

The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer
por: Poduval, Deepak, et al.
Publicado: (2020)

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk
por: Knappskog, Stian, et al.
Publicado: (2011)

BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?
por: Lønning, Per Eystein, et al.
Publicado: (2018)

Correction: The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer
por: Poduval, Deepak, et al.
Publicado: (2021)

CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
por: Chrisanthar, Ranjan, et al.
Publicado: (2008)

TP53 and additional pathways in therapy resistance
por: Lønning, PE
Publicado: (2005)

TP53 Gene Status Affects Survival in Advanced Mycosis Fungoides
por: Wooler, Gitte, et al.
Publicado: (2016)

ramr: an R/Bioconductor package for detection of rare aberrantly methylated regions
por: Nikolaienko, Oleksii, et al.
Publicado: (2021)

epialleleR: an R/Bioconductor package for sensitive allele-specific methylation analysis in NGS data
por: Nikolaienko, Oleksii, et al.
Publicado: (2023)

Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved
por: Lønning, Per Eystein, et al.
Publicado: (2013)

DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response
por: Dejeux, Emelyne, et al.
Publicado: (2010)

Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer
por: Lønning, Per E., et al.
Publicado: (2022)

Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
por: Bjørnslett, Merete, et al.
Publicado: (2012)

Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
por: Knappskog, Stian, et al.
Publicado: (2015)

Adjuvant treatment: the contribution of expression microarrays
por: Lønning, Per Eystein, et al.
Publicado: (2007)

Alterations of the retinoblastoma gene in metastatic breast cancer
por: Berge, Elisabet Ognedal, et al.
Publicado: (2011)

Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2015)

An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2020)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2013)

p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma
por: Boldrin, Elisa, et al.
Publicado: (2023)

Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour
por: Straume, Anne Hege, et al.
Publicado: (2012)

BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study
por: Høberg-Vetti, Hildegunn, et al.
Publicado: (2016)

TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
por: Wang, Y, et al.
Publicado: (2004)

TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy
por: Munch-Petersen, Helga D., et al.
Publicado: (2016)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TP53 Status and Response to Treatment in Breast Cancers
por: Varna, Mariana, et al.
Publicado: (2011)

Prevalence of the CHEK2 R95* germline mutation
por: Knappskog, Stian, et al.
Publicado: (2016)

MDM4 SNP34091 (rs4245739) and its effect on breast‐, colon‐, lung‐, and prostate cancer risk
por: Gansmo, Liv B., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h09430pfsc9cql282kpgn70qog